PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
This research is looking into two conditions called granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). These are rare conditions that cause inflammation in blood vessels. The study wants to find out the best way to stop the condition from flaring up after a period of good health. Researchers are comparing two approaches: 1. **Watching and waiting:** Patients are closely monitored for signs that their condition might be returning. 2. **Early treatment:** Patients are given a medication called rituximab as a preventative measure if certain markers in their blood (called ANCA) suggest a flare-up might happen. The main goal is to see which approach leads to patients staying well for longer, without their condition returning, over a two-year period.
At a glance
What is this study about?
This study is designed to help people living with two uncommon conditions called granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). These conditions cause inflammation in the body's small blood vessels, which can affect many organs. After treatment, patients often go into remission, meaning their symptoms improve or disappear. However, there's always a risk the condition might flare up again.
The main question this study wants to answer is: What's the best way to prevent a relapse (when the condition comes back or gets worse) once a patient's ANCA levels start to rise again? ANCA stands for anti-neutrophil cytoplasm antibodies, which are special markers in the blood. When these levels go up, it can sometimes be an early warning sign that the condition might be returning. The study is comparing two different ways to handle this:
One group of patients will be closely monitored by their doctors, and treatment will only be given if their symptoms or other tests show a definite flare-up. The other group will receive an earlier preventative treatment with a medicine called rituximab (also known as Truxima) if their ANCA levels increase, even before they have clear symptoms. The researchers will then compare both groups over two years to see which approach helps patients stay healthier for longer without their condition returning. They will also look at other important things like side effects, quality of life, and how much steroid medication is needed.
Key takeaways
- The study compares two ways to prevent flare-ups in GPA and MPA.
- It tests if early rituximab treatment is better than close observation when ANCA levels rise.
- The main goal is to see which approach leads to longer periods without the disease returning.
- Participation involves regular clinic visits and monitoring for two years.
- Your quality of life and side effects will also be closely checked.
Who may be eligible?
To join this study, you would need to be an adult, 18 years old or older. The study is open to both men and women.
More specifically, eligible participants will have one of the two conditions being studied: granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
There will also be other specific medical criteria that your doctor will check to make sure the study is a safe and suitable option for you. This might include ensuring your condition is currently stable and that you meet certain health requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)?
- Is your condition currently in remission or stable?
- Are you able to attend regular clinic visits for two years?
What does participation involve?
If you decide to take part in this study, you would be followed closely over a period of 24 months (two years). During this time, you would have regular visits to your clinic where doctors would monitor your health. They would check for any signs of your condition returning and assess for side effects.
Depending on which group you are in, you might receive infusions of rituximab (Truxima) or continue with your current care plan unless a definite flare-up occurs. You would also likely have blood tests to check your ANCA levels and other important markers. Researchers would also ask you to complete questionnaires about your quality of life to understand how the treatments affect your daily living. All visits and treatments would be carefully managed by your study doctor and team.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What are GPA and MPA?
They are rare conditions where the body's immune system attacks small blood vessels, causing inflammation. This can affect organs like the kidneys, lungs, and nerves.
What is 'relapse' in this study?
A relapse means your condition has flared up again or is getting worse. The study will be carefully measuring this using specific medical scores.
What is rituximab (Truxima)?
Rituximab is a medication given by infusion that works by targeting certain immune cells. It's used to treat various conditions, including some autoimmune diseases.
What are ANCA levels?
ANCA are special antibodies in your blood. Levels can rise if your condition is becoming active again. This study is testing how to react when these levels go up.
How long does the study last?
Your participation in the study would involve being followed and monitored for 24 months, which is two years.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.